- Market Capitalization, $K 293,081
- Shares Outstanding, K 149,531
- Annual Sales, $ 53,450 K
- Annual Income, $ -168,840 K
- 60-Month Beta 2.24
- Price/Sales 5.83
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
-0.12 (-5.78%)since 05/24/19
| || |
-0.54 (-22.20%)since 03/22/19
| || |
-10.27 (-84.57%)since 06/22/18
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.
Pomerantz LLP is investigating claims on behalf of investors of ImmunoGen, Inc. ("ImmunoGen" or the "Company") (NASDAQ: IMGN). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org...
--Combination Demonstrates Significant Anti-Tumor Activity and Favorable Safety and Tolerability in Platinum-Resistant Disease
Immunogen Inc (NASDAQ:IMGN) traded in a range yesterday that spanned from a low of $2.09 to a high of $2.20. Yesterday, the shares fell 33.8%, which took the trading range below the 3-day low of $3.07...
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the United States Food and Drug Administration...
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ImmunoGen, Inc. (NASDAQ:IMGN),...
ImmunoGen (IMGN) reports wider-than-expected loss in Q1 and misses revenue estimates.
Medical device and technology development is an area where the U.S. companies are at the forefront. According to a SelectUSA.gov publication, the United States remains the largest medical device market...